Careers  |  Sign In  |  Register

Immune Combo Active in Untreated Melanoma

Combination

A preliminary clinical study looking at previously untreated metastatic melanoma showed promising results when treating with the combination of an IL-2 signaling agonist and nivolumab. Primary trial objectives consisted of safety and tolerability, objective response rate, and a per-protocol efficacy evaluation involving patients with at least one post-baseline radiologic assessment. These results are considered obvious precursors to additional analyses and further studies.

Learn more by clicking here.